DC402234 (FB2001), an anti-SARS-CoV-2 drug candidate mainly developed by research team at the Shanghai Institute of Materia Medica (SIMM) of Chinese Academy of Sciences enters its Phase I clinical trial in the United States on March 15. DC402234, a peptidomimetic compound, was designed and synthesized through analyzing the crystal structure of the coronaviruses Mpro.
A group of local researchers has developed a new drug to treat Lupus, a disease in which the body's immune system mistakenly attacks healthy tissue. And the State Food and Drug Administration has approved the drug for clinical trials.
86-10-68597521 (day)
86-10-68597289 (night)
52 Sanlihe Rd., Xicheng District,
Beijing, China (100864)
Copyright © 2002 - Chinese Academy of Sciences
